Lung Cancer in Spain. Current Epidemiology, Survival, and Treatment;El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales

Archivos de Bronconeumologia

Volumn 45, Issue 7, 2009, Pages 341-348

  Sánchez De Cos Escuín, Julio ^a  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Epidemiology; Lung cancer; Survival; Treatment

Indexed keywords

BEVACIZUMAB; ERLOTINIB;

AGE DISTRIBUTION; AGED; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SEX RATIO; SHORT SURVEY; SPAIN; SURGICAL MORTALITY; SURVIVAL RATE;

ADENOCARCINOMA; AGE DISTRIBUTION; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMORBIDITY; DRUG UTILIZATION; EUROPE; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MASS SCREENING; MORTALITY; PALLIATIVE CARE; PNEUMONECTOMY; SEX DISTRIBUTION; SPAIN; SURVIVAL RATE; UNITED STATES; WAITING LISTS;

EID: 67649447019     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2008.06.005     Document Type: Short Survey

References (86)

1. Instituto Nacional de Estadística. Defunciones según la causa de muerte en España. 2005. Madrid, 2008. Disponible en: http://www.ine.es
2. Fernández E., González J.R., Borrás J.M., Moreno V., Sánchez V., and Peris M. Recent decline in cancer mortality in Catalonia (Spain). A joinpoint regression analysis. Eur J Cancer 37 (2001) 2222-2228
3. Cayuela A., Rodríguez-Domínguez S., and Otero R. Evolución de la mortalidad por cáncer de pulmón en las provincias de Andalucía (1975-2002). Arch Bronconeumol 42 (2006) 633-637
4. Montero C., Rosales M., Otero I., Blanco M., Rodríguez G., Peterga S., et al. Cáncer de pulmón en el Área Sanitaria de A Coruña: incidencia, abordaje clínico y supervivencia. Arch Bronconeumol 39 (2003) 209-216
5. Miravet L., Paradís A., Peláez S., Arnal M., and Cabadés F. Evolución del carcinoma broncopulmonar en el norte de la provincia de Castellón 1993-2002. Arch Bronconeumol 40 (2004) 553-557
6. Alonso-Fernández M.A., García-Clemente M., and Escudero-Bueno C. Características del carcinoma broncopulmonar en una región del norte de España. Arch Bronconeumol 41 (2005) 478-483
7. Hernández Hernández J.R., Tapias del Pozo J.A., Moreno Canelo P., Rodríguez Puebla A., and Sánchez Marcos J.C. Incidencia del cáncer de pulmón en la provincia de Ávila. Año 2002 y tendencias en una década. Arch Bronconeumol 40 (2004) 304-310
8. Abal J., Blanco M.A., Tumbeiro M., García J.M., Prieto P., and Riu M. Estudio epidemiológico clínico del cáncer de pulmón en el año 2003. Arch Bronconeumol 42 Espec Congr (2006) 78
9. Sánchez de Cos Escuín J., Miravet L., Abal J., Núñez A., Hernández J., Castañar A.M., et al. Estudio multicéntrico epidemiológico-clínico de cáncer de pulmón en España (estudio EpicliCP-2003). Arch Bronconeumol 42 (2006) 446-452
10. National Cancer Institute. SEER. Cancer Statistic Review 1975-2001. Disponible en: http://www.staetcancerprofiles.cancer.gov
11. Subramanian J., and Govindan R. Lung cancer in never smokers. A review. J Clin Oncol. 25 (2007) 561-570
12. Wakelee H.A., Chang E.T., Gómez S.L., Keegan T.H., Feskanich D., Clarke C.A., et al. Lung cancer incidence in never smokers. J Clin Oncol 25 (2007) 561-570
13. Gazdar A.F., and Thun M.J. Lung cancer, smoke exposure, and sex. J Clin Oncol 25 (2007) 469-471
14. Thomas L., Doyle A., and Edelman J. Lung cancer in women. Emerging differences in epidemiology, biology and therapy. Chest 128 (2005) 370-381
15. ELCAP investigators. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 296 (2006) 180-184
16. Patel J.D., Bach P.B., and Kris M.G. Lung cancer in US women. A contemporary epidemic. JAMA 291 (2004) 1763-1768
17. Henschke C.I., and Miettinen O.S. Women's susceptibility to tobacco carcinogens. Lung cancer 43 (2004) 1-5
18. Risch H.A., and Miller A.B. Are women more susceptible to lung cancer?. J Natl Cancer Inst 96 (2004) 1560-1561
19. Blot W.J., and McLaughlin J.K. Are women more susceptible to lung cancer?. J Natl Cancer Inst 96 (2004) 812-813
20. Olak J., and Colson Y. Gender differences in lung cancer: have we really come a long way, baby?. J Thorac Cardiovasc Surg 128 (2004) 346-351
21. Bain C., Feskanich D., Speizer F.E., Thun M., Hertzmark E., Rosner B.A., et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96 (2004) 826-834
22. Weir H.K., Thun M.J., Hankey B.F., Ries L.A.G., Howe H.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95 (2003) 1276-1299
23. Janssen-Heijnen M.L.G., Smulders S., Lemmens V.E.P.P., Smeenk F.W.J.M., Van Geffen H.J.A.A., and Coebergh J.W.W. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 59 (2004) 602-607
24. Free C.M., Ellis M., Beggs L., Beggs D., Morgan S.A., and Baldwin D.R. Lung cancer outcomes at a UK cancer unit between 1998-2001. Lung Cancer 57 (2007) 222-228
25. Gregor A., Thomson C.S., Brewster D.H., Stroner P.l., Davidson J., and Fergusson R.J. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 56 (2001) 212-217
26. Mäkitaro R., Pääkko P., Huhti E., Bloigu R., and Kinnula V.L. An epidemiological study of lung cancer: history and histological types in a general population in northern Finland. Eur Respir J 13 (1999) 436-440
27. Koyi H., Hillerdal G., and Brandén E. A prospective study of a total material of lung cancer from a county in Sweden 1997-1999: gender, symptoms,. Type, stage, and smoking habits. Lung Cancer 36 (2002) 9-14
28. Imperatori A., Harrison R.N., Leitch D.N., Rovera F., Lepore G., Dionigi G., et al. Lung cancer in Teesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 61 (2006) 232-239
29. Grupo de estudio del carcinoma broncopulmonar de la SOCALPAR. Incidencia del carcinoma broncopulmonar en Castilla-León durante el año 1997. Estudio multicéntrico de la Sociedad Castellano-Leonesa de Patología Respiratoria (SOCALPAR). Arch Bronconeumol 36 (2000) 313-318
30. Miravet L., Peláez S., Paradis A., Amal M., and Cabades F. Estudio epidemiológico del cáncer pulmonar en el norte de la provincia de Castellón. Arch Bronconeumol 37 (2001) 298-301
31. Sánchez de Cos Escuín J., Disdier Vicente C., Corral Peñafiel J., Riesco Miranda J.A., Sojo González M.A., and Masa Jiménez J.F. Supervivencia global a largo plazo en el cáncer de pulmón. Análisis de una serie de 610 pacientes no seleccionados. Arch Bronconeumol 40 (2004) 268-274
32. Estrada Trigueros G., Comeche L., López Encuentra A., Montoso Zulueta J., González Garrido F., and Colina F. Carcinoma broncogénico 2000-2001. Características y supervivencia global Arch Bronconeumol 43 (2007) 594-598
33. Sánchez de Cos Escuín J., Miravet L., Abal J., Núñez A., Muñoz F.J., García L., et al. Lung cancer survival in Spain: a prospective, multiregional study. Lung Cancer 59 (2008) 246-254
34. Alberg A.J., Ford J.G., and Samet J.M. Epidemiology of lung cancer. ACCP Evidence-Based Clinical Practice Guidelines (2nd edition). Chest 132 (2007) 29S-55S
35. Toh C.K., Gao F., Lim W.T., Leong S.S., Fong K.W., Yap S.P., et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24 (2006) 2245-2251
36. Toh C.K., Gao F., Lim W.T., Leong S.S., Fong K.W., Yap S.P., et al. Differences between small-cell lung cancer and non-small cell lung cancer among tobacco smokers. Lung Cancer 56 (2007) 161-166
37. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006) 4539-4544
38. Ettinger D.S. Changing FACE of small-cell lung cancer: real and artifact. J Clin Oncol 24 (2006) 4526-4527
39. Janssen-Heijnen M.L.G., and Coebergh J.W.W. The changing epidemiology of lung cancer in Europe. Lung Cancer 41 (2003) 245-258
40. Chute C.G., Greenberg E.R., Baron J., Korson R., Baker J., Yates J., et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermons. Cancer 56 (1985) 2107-2112
41. Sánchez de Cos J., Redondo J., and Sever M.A. Carcinoma broncopulmonar. Estudio epidemiológico-clínico de 157 casos. Aten Primaria 6 (1989) 304-311
42. Sánchez de Cos Escuín J., Riesco Miranda J.A., Antón Martínez J., Díez Santamaría P., Márquez Pérez L., Medina Gallardo J.F., et al. Incidencia de carcinoma broncopulmonar en Extremadura durante el año 1998. Arch Bronconeumol 36 (2000) 381-384
43. Manser R.L., Irving L.B., Byrnes G., Abramson M.J., Stone C.A., and Campbell D.A. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax 58 (2003) 784-789
44. ELCAP investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 (2006) 1763-1771
45. Black C., De Verteuil R., Walker S.H., Ayres J., Boland A., Bagust A., et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax 62 (2007) 131-138
46. Pastorino U., Bellomi M., Landoni C., De Fiori E., Arnaldi P., Picchio M., et al. Early lung-cancer detection with spiral CT and positron emisión tomography in heavy smokers: 2-year results. Lancet 362 (2003) 593-597
47. Mac Redmond R., Logan P.M., Lee M., Kenny D., Foley C., and Costello R.V. Screening for lung cancer using low-dose CT scanning. Thorax 59 (2004) 237-241
48. Callol L., Roig F., Cuevas A., De Granda J.I., Villegas F., Jareño J., et al. Low-dose CT: a dose useful and accesible tool for early diagnosis of lung cancer in selected populations. Lung Cancer 56 (2007) 217-221
49. Vierikko T., Järvenpää R., Autti T., Oksa P., Huuskonen M., Kaleva S., et al. Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. Eur Respir J 29 (2007) 78-84
50. Bach P.B., Jett J.R., Pastorino U., Tockman M.S., Swensen S., and Begg C. Computed tomography screening and lung cancer outcomes. JAMA 297 (2007) 953-961
51. Silvestri G.A. Screening for lung cancer in a high-risk group: but I still haven't found what I'm looking for. Eur Respir J 29 (2007) 6-7
52. Phillips A. Resection rates in lung cancer. Thorax 54 (1999) 374
53. Fry W.A., Phillips J.L., and Menck H.R. Ten-year survey of lung cancer treatment and survival in hospital in the United States. Cancer 86 (1999) 1867-1876
54. Verdecchia A., Francisci S., Brenner H., Gatta G., Micheli A., Mangone L., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8 (2007) 784-796
55. Berrino F., DeAngelis R., Sant M., Rosso S., Lasota M.B., Coebergh J.W., et al. Survival for eight major cancers and all cancers combined for European adults diagnoses in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8 (2007) 773-783
56. Debevec L., and Debeljak A. Outcomes of unselected routinely lung cancer patients. Lung cancer 59 (2008) 140-141
57. Damhuis R.A.M., and Schütte P.R. Resection rates and postoperative mortality in 7.899 patients with lung cancer. Eur Respir J 9 (1996) 7-10
58. Mäkitaro R., Pääkko P., Huhti E., Bloigu R., and Kinnula V.L. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J 19 (2002) 1087-1092
59. Moghissi K., and Connolly C.K. Resection rates in lung cancer patients. Eur Respir J 9 (1996) 5-6
60. Laroche C., Wells F., Coulden R., Stewart S., Goddard M., Lowry E., et al. Improving surgical resection rate in lung cancer. Thorax 53 (1998) 445-449
61. Partirdge M.R. Thoracic surgery in a crisis. BMJ 324 (2002) 376-377
62. Sánchez de Cos J, Miravet L, Núñez A, Abal J, Hernández J, Montero C, et al. Lung cancer in Spain. Last epidemiological trends concerning age, gender, smoking prevalence and histological types. Actas de 11th World Conference on Lung Cancer; 2005, julio 3-6; Barcelona.
63. Duque J.L., Gandía F., and Matilla J.M. Morbimortalidad postoperatoria en la cirugía del cáncer de pulmón. In: López Encuentra A., and Llobregat Poyán N. (Eds). Cáncer de pulmón (2002), Doyma, Barcelona 125-141
64. Little A.G., Rusch V.W., and Bonner J.A. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 80 (2005) 2051-2056
65. Strand T.-E., Rostad H., Damhuis R.A.M., and Norstein J. Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude. Thorax 62 (2007) 991-997
66. Duque J.L., Rami-Porta R., Almaraz A., Castanedo M., Freixinet J., Fernández de Rota A., et al. Parámetros de riesgo en la cirugía del carcinoma broncogénico. Arch Bronconeumol 43 (2007) 143-149
67. Sioris T., Sihvo E., Sankila R., and Salo J. Effect of surgical volume and hospital type on outcome in non-small cell lung cancer surgery: a Finnish population-based study. Lung Cancer 59 (2008) 119-125
68. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
69. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355 (2006) 2542-2550
70. Ranson M., Davidson N., Nicolson M., Falk S., Carmichael J., López P., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non small-cell lung cancer. J Natl Cancer Inst 92 (2000) 1074-1080
71. Roszkowski K., Pluzanska A., and Krakowski. A multicenter, randomized phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27 (2000) 145-157
72. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
73. Anderson H., Hopwood R., Stephens R.J., Thatcher N., Cottier B., Nicholson M., et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. Br J Cancer 83 (2000) 447-453
74. Bepler G. Pharmacogenomics: a reality or still a promise?. Lung Cancer 54 Suppl (2006) 3-7
75. Lam W.K., and Watkins N. Lung cancer: future directions. Respirology 12 (2007) 471-477
76. Butler C.A., Darragh K.M., Curries G.P., and Anderson W.J.A. Variation in lung cancer survival rates between countries: do differences in data reporting contribute?. Respir Med 100 (2006) 1642-1646
77. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360 (2002) 1131-1135
78. Strand T.-E., Rostad H., Moller B., and Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 61 (2006) 710-715
79. Treasure T., and Ytley M. Survival after resection for primary lung cancer. Thorax 61 (2006) 649-650
80. Pfannschmidt J., Muley T., Bülzebruck H., Hoffmann H., and Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 55 (2007) 371-377
81. Asamura H., Goya T., Koshiishi Y., Sohara Y., Eguchi K., Mori M., et al. A Japanese lung cancer registry study. Prognosis of 13010 resected lung cancers. J Thorac Oncol 3 (2008) 46-52
82. Mountain C.F. Revisions in the International System for staging lung cancer. Chest 111 (1997) 1710-1717
83. Aragoneses F.G., Moreno N., León P., García-Fontán E., Folqué E., and Bronchogenic Carcinoma cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Influence of delay on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer 36 (2002) 59-63
84. Cañizares Carretero M.A., Rivo Vázquez J.E., Blanco Ramos M., Toscano Novella A., García Fontán E.M., and Parriños Hermida M.J. Influencia de la demora quirúrgica en la supervivencia de los pacientes intervenidos por carcinoma broncogénico. Arch Bronconeumol 43 (2007) 143-149
85. Janes S., and Spiro S. Are we achieving the current waiting time targets in lung cancer treatment?. J Thorac Oncol 2 (2007) 588-589
86. Devbhandari M.P., Bittar M.N., Quennell P., Barber P., Krysiak P., Shah R., et al. Are we achieving the current waiting time targets in lung cancer treatment? Results of a prospective study from a large United Kingdom teaching hospital. J Thorac Oncol 2 (2007) 590-592